Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that Sara Barrington, CEO, will provide a live presentation relating to positive data from the Tuteva™ clinical validation study via the Investor Meet Company platform on 17 June 2022 at 4:30pm BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet VERICI DX PLC via: https://www.investormeetcompany.com/verici-dx-plc/register-investor
Investors who already follow VERICI DX PLC on the Investor Meet Company platform will automatically be invited.Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that an interview with Chief Executive, Sara Barrington, has been published this morning highlighting the positive performance data for Tuteva™, the Company’s post-transplant blood test focused on acute rejection. The interview can be viewed here: https://www.voxmarkets.co.uk/articles/verici-dx-interview-with-ceo-sara-barrington-c2bbfd2/
In the interview, Sara highlights that the data from its blinded, international, multi-centre validation study shows the superior clinical performance of Tuteva™ compared to existing diagnostics “by multiple times” and that the data received a very positive response at the American Transplant Congress (“ATC”) earlier this month.
The interview follows on from the news announced yesterday of further data demonstrating the effectiveness of the test in providing clinicians with actionable information to better inform the medical management of kidney transplant patients. Yesterday’s announcement can be seen here: https://vericidx.com/tuteva-clinical-validation-study/
The positive performance data establishes a new industry standard in detection of acute kidney transplant rejection and paves way for US commercial launch in 2022.
The headline result from the study was originally announced on 12 May, which can be seen here: https://vericidx.com/positive-results-for-tuteva/
Sara Barrington, CEO
Julian Baines, Chairman
Via Walbrook PR
N+1 Singer (Nominated Adviser & Broker)
Aubrey Powell / Kailey Aliyar / Tom Salvesen
Tel: 020 7496 3000
Walbrook PR Limited
Paul McManus / Sam Allen
Tel: 020 7933 8780 or firstname.lastname@example.org
Mob: 07980 541 893 / 07748 651 727